PMID- 28240017
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Print)
IS  - 1513-7368 (Linking)
VI  - 18
IP  - 1
DP  - 2017 Jan 1
TI  - Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - 
      a Prospective Analysis.
PG  - 107-114
AB  - Background: A significant percentage of lung adenocarcinomas have a driver 
      mutation. To date, there has been no assessment of the prevalence of such 
      mutations in a Middle Eastern population. The present multicenter prospective 
      study of formalin fixed paraffin embedded (FFPE) tissues from patients diagnosed 
      with lung adenocarcinoma was performed to assess the prevalence of EGFR and ALK 
      mutations in the Levant. Methods: Patients of Middle Eastern origin with lung 
      adenocarcinomas at 10 sites in Lebanon, Jordan and Iraq were prospectively 
      enrolled. Tumors were tested for EGFR by PCR and for EML4-ALK translocation by 
      fluorescence in situ hybridization (FISH). Results: A total of 210 patients were 
      enrolled, 139 (66.2%) males and 71 females (33.8%), with a mean age of 63.4 
      years. EGFR testing of 205 (97.6%) demonstrated the wild type in 173 (84.4%) and 
      mutated forms in 32 (15.6%). Some 46.9% of EGFR positive patients were 
      non-smokers and 62.5% were females as opposed to 22.4% and 33.8%, respectively, 
      in the general population. As for the EML4-ALK translocation, testing in 157 
      (74.8%) cases gave negative results in 154 (98.1%) , only 3 being positive 
      (1.9%), 2 being females and 2 non-smokers.Conclusion: Our study established a 
      15.6% EGFR mutation rate in lung adenocarcinomas with ALK translocation mutations 
      in only 1.9%, as compared to a 15-20% and 5%, respectively, in the Western 
      literature.
CI  - Creative Commons Attribution License
FAU - Tfayli, Arafat
AU  - Tfayli A
AD  - American University of Beirut Medical Center, Department of Internal Medicine PO 
      Box: 11-0236, Riad El Solh, Beirut 1107 2020, Beirut- Lebanon. Email: 
      at35@aub.edu.lb
FAU - Rafei, Hind
AU  - Rafei H
FAU - Mina, Alain
AU  - Mina A
FAU - Khalil, Maya
AU  - Khalil M
FAU - Fakhreddin, Najla
AU  - Fakhreddin N
FAU - Mahfouz, Rami
AU  - Mahfouz R
FAU - Hamouri, Shadi
AU  - Hamouri S
FAU - Farhat, Fadi
AU  - Farhat F
FAU - Salem, Ziad
AU  - Salem Z
FAU - Dbouk, Haifa
AU  - Dbouk H
FAU - Rabee, Haider
AU  - Rabee H
FAU - Saghir, Nagi
AU  - Saghir N
FAU - Shamseddine, Ali
AU  - Shamseddine A
FAU - Makarem, Jawad
AU  - Makarem J
FAU - Bitar, Nizar
AU  - Bitar N
FAU - Mougharbil, Anas
AU  - Mougharbil A
FAU - Assi, Hazem
AU  - Assi H
FAU - Temraz, Sally
AU  - Temraz S
FAU - Mukherji, Deborah
AU  - Mukherji D
FAU - Matalka, Ismail
AU  - Matalka I
FAU - Zaatari, Ghazi
AU  - Zaatari G
LA  - eng
PT  - Journal Article
DEP - 20170101
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
PMC - PMC5563085
OTO - NOTNLM
OT  - Lung adenocarcinoma
OT  - EGFR mutation
OT  - EML-ALK translocation
OT  - levant area
EDAT- 2017/02/28 06:00
MHDA- 2017/02/28 06:01
PMCR- 2017/03/01
CRDT- 2017/02/28 06:00
PHST- 2017/02/28 06:00 [pubmed]
PHST- 2017/02/28 06:01 [medline]
PHST- 2017/02/28 06:00 [entrez]
PHST- 2017/03/01 00:00 [pmc-release]
AID - APJCP-18-107 [pii]
AID - 10.22034/APJCP.2017.18.1.107 [doi]
PST - epublish
SO  - Asian Pac J Cancer Prev. 2017 Jan 1;18(1):107-114. doi: 
      10.22034/APJCP.2017.18.1.107.